Cargando…
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. In this phase III trial, 286 patients with MM ineligible for ASCT received Rd with or wit...
Ejemplares similares
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019) -
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
por: Mosquera Orgueira, Adrian, et al.
Publicado: (2022) -
Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial
por: Puig, Noemí, et al.
Publicado: (2020) -
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
por: Encinas, Cristina, et al.
Publicado: (2022) -
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)